 Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017322
|
| MeSH Number(s) |
E05.318.760.535.210 E05.337.250.210 N05.715.360.775.235.210 N06.850.520.450.535.210
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 4 | 4 | | 1993 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 4 | 4 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 4 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 4 | 4 | | 2005 | 1 | 7 | 8 | | 2006 | 1 | 4 | 5 | | 2007 | 5 | 2 | 7 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 2 | 6 | | 2010 | 3 | 2 | 5 | | 2011 | 3 | 6 | 9 | | 2012 | 4 | 5 | 9 | | 2013 | 1 | 4 | 5 | | 2014 | 3 | 12 | 15 | | 2015 | 1 | 2 | 3 | | 2016 | 0 | 3 | 3 | | 2017 | 0 | 2 | 2 | | 2018 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Werntz RP, Eggener SE. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183.
-
Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
-
Misiukiewicz K, Gupta V, Posner M. The Italian Collaborative Group sets a standard for the treatment of locally advanced head and neck cancer. Ann Oncol. 2017 09 01; 28(9):2051-2054.
-
Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
-
Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, Gökbuget N, Zugmaier G, Benjamin JE, Zhang A, Jia C, Topp MS. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85.
-
Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
-
Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
-
Lee J, Thall PF, Ji Y, Müller P. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 2016 Apr; 17(2):304-19.
-
Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
-
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|